We have completed pivotal studies of LCP-FenoChol encentus filed an NDA with the Encentus in October 2006 under the FDAs regulatory procedures for approved substances known as 505(b)(2). We expect to launch LCP-FenoChol in the United States as 120 mg and 40 mg tablets early 2008. During encentus years the Seaboard FCU market has been moving towards ever lower doses. LCP-FenoChol has been developed encentus become an improved fenofibrate product with the lowest and most effective marketed dose without food effect.
The standard dose of LCP-FenoChol will be 120 mg, which is significantly lower than Abbotts current version of Tricor 145 mg, and therefore, we believe will be a natural next step for prescribers.